First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Bookmark and Share
Published: 30 May 2015
Views: 1973
Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA.

Prof Sandler presents, at a press conference at ASCO 2015, the results of a federally funded phase III study that found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localised prostate cancer.

Read the news article or watch the video interview for more.